(1R,2S)-2-(2-methoxybenzylamino)-1-phenylpropan-1-ol | 150917-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2S)-2-(2-methoxybenzylamino)-1-phenylpropan-1-ol
• 英文别名: (1R,2S)-1-Hydroxy-1-phenyl-2-[(2-methoxy)-phenyl-methylamino]propane；(1R,2S)-2-[(2-methoxyphenyl)methylamino]-1-phenylpropan-1-ol
• CAS: 150917-22-9
• 化学式: C₁₇H₂₁NO₂
• 分子量: 271.359
• InChiKey: SKFKVJBOGIQGCP-GUYCJALGSA-N

物化性质

• 熔点：
  90-92 °C(Solvent: Diethyl ether; Hexane)
• 沸点：
  409.7±24.0 °C(predicted)
• 密度：
  1.096±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 (1R,2S)-2-(2-methoxybenzylamino)-1-phenylpropan-1-ol
  参考文献：
  名称：

  β-Amino alcohols derived from (1R,2S)-norephedrine and (1S,2S)-pseudonorephedrine as catalysts in the asymmetric addition of diethylzinc to aldehydes

  摘要：

  A family of N-alkylnorephedrine and N-alkylpseudonorephedrine derived ligands were prepared and applied in the asymmetric alkylation of benzaldehyde using diethylzinc. The absolute configuration of the addition product was directed primarily by the benzylic position of the Ephedra alkaloid, while the magnitude of the enantiomeric ratio was heavily influenced by the nitrogen substituent. However, sterically demanding substituents at the nitrogen position caused the enantioselectivity to be the same for the two diastereomeric systems. Among the ligands that were prepared, it was determined that the N-cyclooctylpseudonorephedrine derivative 7b yielded the highest enantiomeric ratios (87.5:12.5 to 91.0:9.0) when applied in the catalytic asymmetric addition of diethylzinc to aldehydes. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2007.11.027

文献信息

• Acyclic ethylenediamine derivatives
  申请人：Pfizer Inc.

  公开号：US05521220A1

  公开（公告）日：1996-05-28

  The present invention relates to novel acyclic ethylenediamine derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are defined as in the specification. It also relates to novel intermediates used in the synthesis of such derivatives. Compounds of the formula I and their pharmaceutically acceptable salts are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

  本发明涉及新型含氮杂环化合物的无环乙二胺衍生物，具体而言，涉及式I的化合物，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和R.sup.6如规范中所定义。它还涉及用于合成这类衍生物的新型中间体。式I的化合物及其药学上可接受的盐在治疗炎症和中枢神经系统疾病以及其他疾病中是有用的。